Elsevier

The Lancet

Volume 350, Issue 9071, 12 July 1997, Pages 117-118
The Lancet

Research Letters
New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer

https://doi.org/10.1016/S0140-6736(05)61821-1Get rights and content

References (5)

  • P Tonin et al.

    BRCA1 mutations in Ashkenazi Jewish women

    Am J Hum Genet

    (1995)
  • K Offit et al.

    Germline BRCA1 185delAG mutations in Jewish women with breast cancer

    Lancet

    (1996)
There are more references available in the full text version of this article.

Cited by (15)

  • Genetic tests to identify risk for breast cancer

    2015, Seminars in Oncology Nursing
    Citation Excerpt :

    The National Comprehensive Cancer Network (NCCN) 2014 guidelines on genetic/familial high-risk assessment in breast and ovarian cancer outline the criteria for multi-gene testing in breast cancer, specifically pointing to the clinical relevance of the TP53, PTEN, ATM, and PALB2 genes, in addition to BRCA1 and BRCA2.9 Genetic tests currently on the market are detailed in Table 12,6,10-28 with their corresponding trade names. These tests screen for known point mutations, small deletions, and large chromosomal rearrangements.

  • Hereditary breast cancer

    2001, Current Problems in Surgery
  • Obtaining and using genetic information

    2011, Inherited Cancer Syndromes: Current Clinical Management
View all citing articles on Scopus
View full text